
A study on 40 adults with type 1 diabetes found that faster-acting insulin aspart improved glucose control, reducing time above range and HbA1c while maintaining safety. After 16 weeks of pump therapy, it showed better time in range (TIR) and variability but caused more injection site reactions. Faster aspart may offer improved diabetes management with frequent dose adjustments.
Like
Save
Share